PT - JOURNAL ARTICLE AU - Andrea M. Pallotta AU - ChungYun Kim AU - Steven M. Gordon AU - Alice Kim TI - Monoclonal antibodies for treating COVID-19 AID - 10.3949/ccjm.88a.ccc074 DP - 2021 Feb 17 TA - Cleveland Clinic Journal of Medicine 4099 - http://www.ccjm.org/content/early/2021/02/17/ccjm.88a.ccc074.short 4100 - http://www.ccjm.org/content/early/2021/02/17/ccjm.88a.ccc074.full AB - Bamlanivimab and casirivimab-imdevimab are novel virus-neutralizing monoclonal antibodies authorized to treat mild to moderate COVID-19 in outpatients at risk for progression to severe disease. Treatment early in the disease may show efficacy in reducing progression to severe disease, although safety and efficacy data are limited. They are not authorized for hospitalized patients with more advanced disease.